Sfoglia per RIVISTA
TARGETED ONCOLOGY
Collezione AO Ordine Mauriziano
Items : 2
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. in Targeted oncology / Target Oncol. 2016 Jun;11(3):429. doi: 10.1007/s11523-016-0433-x.
2016
AO Ordine Mauriziano
Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Green JA; Steer C; Berns EM; Casado A; Lambrechts D; Jimeno A;
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. in Targeted oncology / Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6.
2015
AO Ordine Mauriziano
Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Berns EM; Casado A; Lambrechts D; Jimeno A;